4.Research progress of virtual screening aided drug discovery.
Acta Pharmaceutica Sinica 2009;44(6):566-570
In the process of new drug discovery, the application of virtual screening can enrich active compounds, reduce the cost of drug screening, and increase the feasibility of drug screening. Therefore virtual screening technology has become an important approach for new drug discovery. As virtual screening and bioactivity screening possess different advantages, their combination can effectively promote new drug discovery. In the present paper, the application and the trend of removal of non-drug compounds, removal of false positive compounds, pharmacophore searching, molecular docking, and molecular similarity in the process of drug discovery are introduced in order to obtain more benefit from virtual screening strategy for new drug discovery.
Drug Design
;
Drug Discovery
;
Drug Evaluation, Preclinical
;
Models, Molecular
5.Caenorhabditis elegans: a powerful tool for drug discovery.
Acta Pharmaceutica Sinica 2009;44(7):687-694
A simple model organism Caenorhabditis elegans has contributed substantially to the fundamental researches in biology. In an era of functional genomics, nematode worm has been developed into a multi-purpose tool that can be exploited to identify disease-causing or disease-associated genes, validate potential drug targets. This, coupled with its genetic amenability, low cost experimental manipulation and compatibility with high throughput screening in an intact physiological condition, makes the model organism into an effective toolbox for drug discovery. This review shows the unique features of C. elegans, how it can play a valuable role in our understanding of the molecular mechanism of human diseases and finding drug leads in drug development process.
Animals
;
Caenorhabditis elegans
;
Drug Discovery
;
Drug Evaluation, Preclinical
6.The authorized considerations on the pre-clinical study of drug-eluting coronary stent system.
Maobo CHENG ; Xinli SHI ; Jianxiong JIA ; Jingjing MIAO ; Wei LIU ; Feilong NIE
Chinese Journal of Medical Instrumentation 2014;38(6):461-462
China Food and Drug Administration didn't issue any guideline on the pre-clinical study of drug-eluting coronary stent system, the basic requirement of the authorized administration was summarized to help manufacture prepare the document during the registration process.
China
;
Drug Evaluation, Preclinical
;
methods
;
Drug-Eluting Stents
;
Guidelines as Topic
10.Proteomics in post-genome era and its application in pharmacy.
Acta Pharmaceutica Sinica 2002;37(10):828-832
Result Analysis
Print
Save
E-mail